康寧傑瑞製藥-B(09966.HK)採納購股權計劃
格隆匯4月14日丨康寧傑瑞製藥-B(09966.HK)公佈,公司計劃根據香港聯合交易所有限公司證券上市規第17章採納購股權計劃,以向首次公開發售後購股權計劃的承授人提供獲取公司所有權權益的機會,藉此激勵承授人為提升公司價值而努力工作,從而使公司及其股東整體受益。
首次公開發售後購股權計劃須待香港聯合交易所有限公司上市委員會批准根據首次公開發售後購股權計劃授出的購股權獲行使後可能發行的公司股份上市及買賣;及股東於公司為考慮及酌情批准首次公開發售後購股權計劃而將予召開的股東大會上批准後,方可作實。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.